- Home
- ATYR vs SST Comparison
ATYR vs SST Comparison
Compare ATYR & SST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- SST
- Stock Information
- Founded
- ATYR 2005
- SST 2013
- Country
- ATYR United States
- SST United States
- Employees
- ATYR N/A
- SST N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- SST Diversified Commercial Services
- Sector
- ATYR Health Care
- SST Consumer Discretionary
- Exchange
- ATYR Nasdaq
- SST Nasdaq
- Market Cap
- ATYR 77.1M
- SST 67.7M
- IPO Year
- ATYR 2015
- SST N/A
- Fundamental
- Price
- ATYR $0.71
- SST $3.63
- Analyst Decision
- ATYR Buy
- SST Strong Buy
- Analyst Count
- ATYR 6
- SST 1
- Target Price
- ATYR $8.75
- SST $10.00
- AVG Volume (30 Days)
- ATYR 3.8M
- SST 23.8K
- Earning Date
- ATYR 11-06-2025
- SST 11-05-2025
- Dividend Yield
- ATYR N/A
- SST N/A
- EPS Growth
- ATYR N/A
- SST N/A
- EPS
- ATYR N/A
- SST N/A
- Revenue
- ATYR $190,000.00
- SST $289,784,000.00
- Revenue This Year
- ATYR $420.85
- SST N/A
- Revenue Next Year
- ATYR $1,513.40
- SST $12.20
- P/E Ratio
- ATYR N/A
- SST N/A
- Revenue Growth
- ATYR N/A
- SST N/A
- 52 Week Low
- ATYR $0.68
- SST $2.90
- 52 Week High
- ATYR $7.29
- SST $15.00
- Technical
- Relative Strength Index (RSI)
- ATYR 29.54
- SST 27.12
- Support Level
- ATYR $0.68
- SST $3.46
- Resistance Level
- ATYR $0.77
- SST $4.95
- Average True Range (ATR)
- ATYR 0.06
- SST 0.44
- MACD
- ATYR 0.03
- SST -0.10
- Stochastic Oscillator
- ATYR 11.19
- SST 13.31
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.